Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303

被引：0
|
作者：
Kobayashi, D. [1 ]
Enomoto, A. [2 ]
Mochizuki, Y. [3 ]
Matsui, T. [4 ]
Nakayama, H. [5 ]
Kawase, Y. [6 ]
Ishigure, K. [7 ]
Shikano, T. [8 ]
Torii, K. [9 ]
Kodera, Y. [1 ]
机构：
[1] Nagoya Univ, Grad Sch Med, Gastroenterol Surg, Nagoya, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Pathol, Nagoya, Aichi, Japan
[3] Komaki Municipal Hosp, Dept Surg, Komaki, Japan
[4] Aichi Canc Ctr Hosp, Dept Surg, Okazaki, Aichi, Japan
[5] Natl Hosp Org, Dept Surg, Nagoya Med Ctr, Nagoya, Aichi, Japan
[6] Tosei Gen Hosp, Dept Surg, Seto, Japan
[7] Konan Kosei Hosp, Dept Surg, Konan, Japan
[8] Yokkaichi Municipal Hosp, Dept Surg, Yokaichi, Japan
[9] Nakatsugawa Municipal Gen Hosp, Dept Surg, Nakatsugawa, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
696P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).
    Mochizuki, Yoshinari
    Kobayashi, Daisuke
    Kojima, Hiroshi
    Nakayama, Hiroshi
    Kawase, Yoshihisa
    Ishigure, Kiyoshi
    Shikano, Toshio
    Torii, Koji
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303)
    Kobayashi, Daisuke
    Mochizuki, Yoshinari
    Torii, Koji
    Takeda, Shin
    Kawase, Yoshihisa
    Ishigure, Kiyoshi
    Teramoto, Hitoshi
    Ando, Masahiko
    Kodera, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1793 - 1799
  • [3] Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303)
    Daisuke Kobayashi
    Yoshinari Mochizuki
    Koji Torii
    Shin Takeda
    Yoshihisa Kawase
    Kiyoshi Ishigure
    Hitoshi Teramoto
    Masahiko Ando
    Yasuhiro Kodera
    International Journal of Clinical Oncology, 2020, 25 : 1793 - 1799
  • [4] SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
    Hidalgo, Manuel
    Plaza, Carlos
    Musteanu, Monica
    Illei, Peter
    Brachmann, Carrie B.
    Heise, Carla
    Pierce, Daniel
    Lopez-Casas, Pedro P.
    Menendez, Camino
    Tabernero, Josep
    Romano, Alfredo
    Wei, Xinyu
    Lopez-Rios, Fernando
    Von Hoff, Daniel D.
    CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4811 - 4818
  • [5] Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
    Takashima, Atsuo
    Shitara, Kohei
    Fujitani, Kazumasa
    Koeda, Keisuke
    Hara, Hiroki
    Nakayama, Norisuke
    Hironaka, Shuichi
    Nishikawa, Kazuhiro
    Kimura, Yutaka
    Amagai, Kenji
    Fujii, Hirofumi
    Muro, Kei
    Esaki, Taito
    Choda, Yasuhiro
    Takano, Toshimi
    Chin, Keisho
    Sato, Atsushi
    Goto, Masahiro
    Fukushima, Norimasa
    Hara, Takuo
    Machida, Nozomu
    Ohta, Manabu
    Boku, Narikazu
    Shimura, Masashi
    Morita, Satoshi
    Koizumi, Wasaburo
    GASTRIC CANCER, 2019, 22 (01) : 155 - 163
  • [6] Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
    Atsuo Takashima
    Kohei Shitara
    Kazumasa Fujitani
    Keisuke Koeda
    Hiroki Hara
    Norisuke Nakayama
    Shuichi Hironaka
    Kazuhiro Nishikawa
    Yutaka Kimura
    Kenji Amagai
    Hirofumi Fujii
    Kei Muro
    Taito Esaki
    Yasuhiro Choda
    Toshimi Takano
    Keisho Chin
    Atsushi Sato
    Masahiro Goto
    Norimasa Fukushima
    Takuo Hara
    Nozomu Machida
    Manabu Ohta
    Narikazu Boku
    Masashi Shimura
    Satoshi Morita
    Wasaburo Koizumi
    Gastric Cancer, 2019, 22 : 155 - 163
  • [7] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study
    Von Hoff, D. D.
    Ramanathan, R.
    Borad, M.
    Laheru, D.
    Smith, L.
    Wood, T.
    Korn, R.
    Desai, N.
    Iglesias, J.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] NAB-PACLITAXEL IN THE TREATMENT OF ADVANCED PANCREATIC CANCER REFRACTORY TO GEMCITABINE - FINAL RESULTS OF A PHASE 2 TRIAL
    Lopes, G. de Lima
    Hosein, P.
    Gomez, C.
    Pastorini, V.
    Macintyre, J.
    Easey, M.
    Reis, I.
    Merchan, J.
    Bejarano, P.
    Rocha-Lima, C.
    EJC SUPPLEMENTS, 2011, 9 (01): : 1 - 1
  • [9] SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC)
    Yardley, D. A.
    Daniel, B. R.
    Inhorn, R. C.
    Vazquez, E. R.
    Trieu, V. N.
    Motamed, K.
    Hwang, L.
    Rugo, H. S.
    Desai, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Nab-paclitaxel as second line treatment in advanced gastric cancer: A HORG multicenter phase II study
    Katsaounis, P.
    Kentepozidis, N.
    Kotsakis, A.
    Polyzos, A.
    Vamvakas, L.
    Bakogiorgos, M.
    Boukovinas, I.
    Hartabilas, E.
    Prinarakis, E.
    Skaltsi, T.
    Georgoulias, V.
    Souglakos, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345